Studienübersicht

Home/Patienten/Klinische Studien/Studienübersicht

Aktuelle Angebote.

Glioblastom (GBM)

Kurztitel Beschreibung Studiendesign Tumor Status
N2M2 Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation: NCT Neuro Master Match – N²M² (NOA-18) Phase I/II GBM (MGMT unmethylated) recruiting
A Study of LY3200882 in Participants With Solid Tumors Phase I Solid Tumors, recurrent GBM follow-up
TIGER Studie zur Anwendung von TTFields in der klinischen Routine, bei Patientinnen und Patienten mit einem neudiagnostizierten Glioblastom (GBM) in Deutschland non-interventionell GBM follow-up
EORTC 1419 Molekulare und klinische Faktoren des Langzeitüberlebens bei Glioblastomen non-interventionell GBM recruiting
AMPLIFY-NEOVAC AMPLIFYing NEOepitope-specific VACcine Responses in progressive diffuse glioma – a randomized, open label, 3 arm multicenter Phase I trial to assess safety, tolerability and immunogenicity of IDH1R132H-specific peptide vaccine in combination with checkpoint inhibitor Avelumab (AMPLIFY-NEOVAC) Phase I recurrent Glioma Grade II-IV (Astrocytoma, Oligodendroglioma, GBM) recruiting
PriCoTTF PriCoTTF Trial: A phase I/II trial of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma Phase I/II GBM recruiting
SNOXA12C401 (GLORIA) Single-arm, dose-escalation, Phase 1/2 study of olaptesed pegol (NOX-A12) in combination with irradiation in inoperable or partially resected first-line glioblastoma patients with unmethylated MGMT promoter Phase I/II GBM (MGMT unmethylated) recruiting

Astrozytome / Oligodendrogliome WHO II-III

Kurztitel Beschreibung Studiendesign Tumor Status
OT-15-001 (STELLAR) A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy Phase III recurrent Anaplastic Astrocytoma recruiting
GliProPh Randomisierte Studie zum Vergleich einer Protonen- vs. Photonen- Strahlentherapie für Patienten mit WHO Grad II-III Gliomen (GliProPh) randomisiert, Berufsordnung Glioma Grade II-III (Astrocytoma, Oligodendroglioma) recruiting
A Study of LY3200882 in Participants With Solid Tumors Phase I Solid Tumors, recurrent GBM follow-up
AG881-C-004 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects Phase III Residual or recurrent Grade II Glioma recruiting
With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation

Melanom

Kurztitel Beschreibung Studiendesign Tumor Status
Neuroimmunologische Nebenwirkung von Checkpoint-Inhibitoren non-interventionell Melanoma recruiting